Dr. Reddy's Laboratories (USA) Inc.
GPTKB entity
Statements (63)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:acquisition |
gptkb:Betapharm_Arzneimittel_Gmb_H
gptkb:Octo_Plus_N._V. Cipla's US subsidiary |
| gptkbp:ceo |
gptkb:Erez_Israeli
|
| gptkbp:employees |
Over 1,000
|
| gptkbp:focus |
gptkb:Geriatrics
gptkb:diabetes gptkb:Ophthalmology gptkb:Oncology gptkb:Pediatrics gptkb:supply_chain_management gptkb:psychology Anesthesiology Gastroenterology Health economics Immunology Pain management Transplantation Urology Clinical trials Neurology Quality assurance Infectious diseases Corporate social responsibility Endocrinology Hematology Orthopedics Preventive care Business development Dermatology Regulatory affairs Chronic diseases Market access Patient support programs Cardiovascular Respiratory Health care services Pharmacovigilance Women’s health Anti-infectives Men’s health Acute diseases Medical affairs |
| gptkbp:founded |
gptkb:1984
|
| gptkbp:founder |
Dr. K. Anji Reddy
|
| gptkbp:headquarters |
gptkb:Princeton,_New_Jersey,_USA
|
| https://www.w3.org/2000/01/rdf-schema#label |
Dr. Reddy's Laboratories (USA) Inc.
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:market |
gptkb:North_America
|
| gptkbp:parent_company |
Dr. Reddy's Laboratories Limited
|
| gptkbp:partnership |
Various global pharmaceutical companies
|
| gptkbp:products |
Active pharmaceutical ingredients
Generic medications |
| gptkbp:research_and_development |
gptkb:Yes
|
| gptkbp:revenue |
$2.5 billion (2020)
|
| gptkbp:services |
Contract manufacturing
|
| gptkbp:stock_exchange |
gptkb:NYSE
|
| gptkbp:stock_symbol |
RDY
|
| gptkbp:subsidiary |
Dr. Reddy's Laboratories Limited
|
| gptkbp:website |
www.drreddys.com
|
| gptkbp:bfsParent |
gptkb:Dr._Reddy's_Laboratories
|
| gptkbp:bfsLayer |
5
|